What is Verve Therapeutics?
Verve Therapeutics is a cardiovascular gene editing company company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Cardiovascular gene editing company
- Headquarters
- Boston, United States
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: VERV
What is Verve Therapeutics?
Verve Therapeutics is a cardiovascular gene editing company company headquartered in Boston, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Verve Therapeutics is a cardiovascular gene editing company company headquartered in Boston, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Verve Therapeutics should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Verve Therapeutics offer?
Verve Therapeutics's profile centers on Base editing, Cardiovascular disease, Genetic medicines, Clinical development.
- Base editing· Cardiovascular gene editing company
- Cardiovascular disease· Cardiovascular gene editing company
- Genetic medicines· Cardiovascular gene editing company
- Clinical development· Cardiovascular gene editing company
- Lipid disorders· Cardiovascular gene editing company
- Platform technology· Cardiovascular gene editing company
How does Verve Therapeutics make money?
Verve Therapeutics makes money through commercial activity tied to cardiovascular gene editing company.
Verve Therapeutics monetizes through the model common to cardiovascular gene editing company: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Verve Therapeutics?
Verve Therapeutics's named executives should be verified on the official leadership or investor-relations page before outreach.
- Verve Therapeutics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Verve Therapeutics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Verve Therapeutics operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Verve Therapeutics's leadership?
Verve Therapeutics should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.vervetx.com- Verve Therapeutics investor relationsInvestor relations / corporate contactcontact via https://www.vervetx.com
- Verve Therapeutics media relationsMedia or communications contact routecontact via https://www.vervetx.com
How is Verve Therapeutics funded?
Verve Therapeutics's current status is Public company; Nasdaq: VERV.
Verve Therapeutics's capital profile is best understood through its current public-company status: Public company; Nasdaq: VERV. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Verve Therapeutics get here?
Verve Therapeutics's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingVerve Therapeutics is foundedThe company begins building in cardiovascular gene editing company.
- Scale-upCommercial footprint expandsVerve Therapeutics broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: VERVPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Verve Therapeutics's competitors?
Verve Therapeutics competes with larger incumbents and focused specialists in cardiovascular gene editing company.
Verve Therapeutics — frequently asked questions
